Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503774 | 0.85 | BTK (0.40) | BTKKDM1AMAOBRORCCTSK | |
| SCHEMBL14100893 | 0.80 | BTK (0.49) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL18901529 | 0.80 | BTK (0.49) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL2943335 | 0.79 | RORC (0.38) | BTKKDM1AMAOBRORCCTSK | |
| SCHEMBL6418270 | 0.77 | BTK (0.51) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL24623231 | 0.76 | BTK (0.49) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL21184415 | 0.76 | BTK (0.49) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL27343830 | 0.76 | BTK (0.49) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL556948 | 0.76 | BTK (0.49) | BTKKDM1AMAOBCTSKNFKB1 | |
| SCHEMBL19932164 | 0.76 | BTK (0.49) | BTKKDM1AMAOBCTSKNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | BTK 1281/4885KDM1A 3565/4885MAOB 2147/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | BTK 1117/4885KDM1A 3445/4885MAOB 2668/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | BTK 1281/4885KDM1A 3565/4885MAOB 2147/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | BTK 420/4885KDM1A 1134/4885MAOB 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.